Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Southern California Desert Retina Consultants, MC
- Study ID
- NCT01722656
- Phase
- PHASE4
- Status
- Completed
Conditions
- Submacular Vascularized Pigment Epithelial Detachments
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Aflibercept — DRUG
Study Details
This study will evaluate the use of intravitreal aflibercept (anti-VEGF therapy) in patients with a type of macular degeneration known as vascularized pigment epithelial detachment. Previous studies have shown a generally poor outcome in treating this difficult to treat form of wet macular degeneration. More recently, multiple pilot studies have shown positive benefits to using anti-VEGF therapy. This study will evaluate the safety and efficacy of treating vascularize pigment epithelial detachment associated with wet macular degeneration with intravitreal aflibercept injection.
Key Dates
- Start date
- Nov 30, 2012
- Status verified
- Jan 2016
- Primary completion
- Sep 30, 2015
- Completion
- Sep 30, 2015
Study Design
- Enrollment
- 40 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Other: AfliberceptAll subjects will receive aflibercept
Primary Outcome Measure
Visual Acuity [ Time Frame: 12 months ]
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Jules Stein Eye Institute | Los Angeles | California | 90095 | - |
| Southern California Desert Retina Consultants | Palm Desert | California | 92211 | - |
| Black Hills Regional Eye Institute | Rapid City | South Dakota | 57701 | - |